NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
Updated: Jul 12, 2022
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide (R) and dexamethasone (d) in patients with relapsed/refractory (R/R) multiple myeloma (MM). The primary objective is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT), the maximum tolerated dose (MTD) and the recommended dose (RP2D) of APG-2575 monotherapy or in combination with Rd in Chinese R/R MM patients.
Sponsor
Location
China
ClinicalTrials.gov Identifier: NCT04674514
Official Title: Phase Ib / II Open-Label Stduy of APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted: December 19, 2020
Click here for details on ClinicalTrials.gov
Drug: APG-2575
Drug: Rd
Lisaftoclax (Code C156249)
APG 2575
APG-2575
APG2575
Bcl-2 Inhibitor APG 2575
Lisaftoclax
LISAFTOCLAX
Locations
China, Beijing
China, Guangdong
China, Henan
China, Hubei
China, Jiangsu
China, Zhejiang